Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
has quickly reshaped how both Wall Street and institutional investors are looking at the stock. See our latest analysis for Recursion Pharmaceuticals. Despite the TUPELO readout, recent insider selling and the upcoming CEO transition have kept sentiment choppy. The share price is at $4.26 and the 1 year total shareholder return is negative 29.35 percent, suggesting long term holders are still under water even as near term momentum shows early signs of stabilizing. If this kind of high risk biotech story interests you, it can be worth comparing Recursion against other innovative healthcare names using healthcare stocks With the stock still down sharply over 12 months yet trading at a roughly 35 percent discount to average analyst targets, is Recursion an overlooked AI biotech on sale, or has the market already priced in its future growth? With Recursion closing at 4.26 dollars and the most popular narrative pointing to fair value around 7 dollars, the upside case leans heavil
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- How Investors May Respond To Recursion Pharmaceuticals (RXRX) Early FAP Trial Success And AI Platform Validation [Yahoo! Finance]Yahoo! Finance
- Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025 [Seeking Alpha]Seeking Alpha
- Recursion Pharmaceuticals (NASDAQ:RXRX) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $11.00 price target on the stock, up previously from $10.00.MarketBeat
- Recursion Pharmaceuticals (NASDAQ:RXRX) was given a new $11.00 price target on by analysts at UBS Group AG.MarketBeat
RXRX
Earnings
- 11/5/25 - Beat
RXRX
Sec Filings
- 12/19/25 - Form 4
- 12/19/25 - Form 144
- 12/17/25 - Form 4
- RXRX's page on the SEC website